News headlines about Baxter International (NYSE:BAX) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Baxter International earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 46.6238891261907 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Analysts Expect Baxter International Inc (BAX) Will Announce Quarterly Sales of $2.62 Billion (americanbankingnews.com)
- Critical Survey: Utah Medical Products (UTMD) versus Baxter International (BAX) (americanbankingnews.com)
- Worldwide Nerve Regeneration Market | Applications – Surgery, Prognosis, Autologous Nerve Grafting | Professional Survey | Forecast till 2023 (medgadget.com)
- Brokerages Anticipate Baxter International Inc (BAX) Will Post Earnings of $0.62 Per Share (americanbankingnews.com)
- Global Blood Plasma Market Anticipated Significant Growth by 2020 with CAGR of 10.54% (medgadget.com)
BAX stock traded up $0.30 during midday trading on Friday, reaching $67.89. The company had a trading volume of 4,332,818 shares, compared to its average volume of 2,760,921. Baxter International has a fifty-two week low of $51.03 and a fifty-two week high of $72.58. The firm has a market capitalization of $36,670.04, a PE ratio of 52.63, a P/E/G ratio of 1.96 and a beta of 0.82. The company has a quick ratio of 2.05, a current ratio of 2.57 and a debt-to-equity ratio of 0.38.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 2nd. Investors of record on Friday, March 2nd will be paid a dividend of $0.16 per share. The ex-dividend date is Thursday, March 1st. This represents a $0.64 annualized dividend and a yield of 0.94%. Baxter International’s dividend payout ratio is currently 49.61%.
Baxter International declared that its Board of Directors has initiated a stock repurchase program on Tuesday, February 20th that permits the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.
Several analysts recently weighed in on BAX shares. Royal Bank of Canada restated a “hold” rating and set a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Bank of America restated a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Zacks Investment Research downgraded Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase & Co. upgraded Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Finally, Evercore ISI initiated coverage on Baxter International in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $71.00.
In other Baxter International news, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Carole J. Shapazian sold 4,990 shares of the stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $66.05, for a total value of $329,589.50. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Baxter International (NYSE:BAX) Share Price” was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/18/baxter-international-bax-receiving-somewhat-favorable-news-coverage-analysis-finds/2012189.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.